Long-term results of angioplasty vs stenting in cardiac transplant recipients with allograft vasculopathy

被引:51
|
作者
Simpson, L [1 ]
Lee, EK [1 ]
Hott, BJ [1 ]
Vega, DJ [1 ]
Book, WM [1 ]
机构
[1] Emory Univ, Sch Med, Dept Internal Med, Div Cardiol, Atlanta, GA 30322 USA
来源
关键词
D O I
10.1016/j.healun.2004.10.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Allograft vasculopathy remains a major limiting factor in long-term graft survival. The absence of symptoms and diffuse nature of the disease make clinical detection and therapy more difficult. Limited data exist on the long-term outcome of percutaneous interventions in this group of patients. Methods: Medical records and cardiac catheterizations from the Cardiac Cath Lab database were retrospectively reviewed for all cardiac transplant recipients who had undergone a percutaneous intervention. Procedural results, complications, use of stents and angiographic follow-up were recorded. Re-stenosis was defined as a lesion > 50% in the target vessel at follow-up angiography. Results: Thirty-three patients underwent 97 percutaneous interventions with a mean of 2.9 interventions per patient. Mean age at the time of first intervention was 52 +/- 13 (mean +/- standard deviation) years. Mean time from transplant to first intervention was 5 +/- 3.0 years. The primary procedural success rate was 99%. Thirty-four procedures involved placement of a stent, 63 were angioplasty alone. There were no procedure-related complications. Seventy percent of lesions were de novo and 30% were re-stenotic lesions. Six-month, 12-month and 5-year target vessel re-stenosis rates in the stent group were 31%, 46% and 69%, and in the percutaneous transluminal coronary angioplasty (PTCA) group were 41%, 53% and 68%, respectively. Thirteen patients (39.3%) died or were re-transplanted, at 1.9 +/- 2.29 (mean SD) years after their first intervention. Twenty patients were alive at 4.5 +/- 2.99 years after the first intervention. Conclusions: Percutaneous intervention can be performed safely in cardiac transplant recipients. Stent placement reduces early and mid-term re-stenosis, but late re-stenosis occurs in 76% of lesions. Late re-stenosis, development of new coronary lesions, and need for repeat intervention are common, regardless of the method used for percutaneous intervention, emphasizing the diffuse and progressive nature of transplant coronary disease.
引用
收藏
页码:1211 / 1217
页数:7
相关论文
共 50 条
  • [41] Long-Term Mortality After Cardiac Allograft Vasculopathy Implications of Percutaneous Intervention
    Agarwal, Shikhar
    Parashar, Akhil
    Kapadia, Samir R.
    Tuzcu, E. Murat
    Modi, Dhruv
    Starling, Randall C.
    Oliveira, Guilherme H.
    JACC-HEART FAILURE, 2014, 2 (03) : 281 - 288
  • [42] Association of Clinical Rejection Vs Rejection on Protocol Biopsy With Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients
    Asimacopoulos, Eleni P.
    Garbern, Jessica C.
    Gavreau, Kimberlee
    Bastardi, Heather J.
    Daly, Kevin P.
    Blume, Elizabeth D.
    Singh, Tajinder P.
    CIRCULATION, 2018, 138
  • [43] Long-term results of subtotal vs total parathyroidectomy without autotransplantation in kidney transplant recipients
    Rayes, Nada
    Seehofer, Daniel
    Schindler, Ralf
    Reinke, Petra
    Kahl, Andreas
    Ulrich, Frank
    Neuhaus, Peter
    Nuessler, Natascha C.
    ARCHIVES OF SURGERY, 2008, 143 (08) : 756 - 761
  • [44] Lifestyle and health status in long-term cardiac transplant recipients
    Salyer, J
    Sneed, G
    Corley, MC
    HEART & LUNG, 2001, 30 (06): : 445 - 457
  • [45] Lifestyle and quality of life in long-term cardiac transplant recipients
    Salyer, J
    Flattery, MP
    Joyner, PL
    Elswick, RK
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2003, 22 (03): : 309 - 321
  • [46] Donor-Specific HLA Alloantibodies: Long-Term Impact on Cardiac Allograft Vasculopathy and Mortality After Heart Transplant
    Kaczmarek, Ingo
    Deutsch, Marcus-Andre
    Kauke, Teresa
    Beiras-Fernandez, Andres
    Schmoeckel, Michael
    Vicol, Calin
    Sodian, Ralf
    Reichart, Bruno
    Spannagl, Michael
    Ueberfuhr, Peter
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2008, 6 (03) : 229 - 235
  • [47] Aspirin Use and the Development of Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients
    D'Addese, L.
    Cantor, R.
    Koehl, D.
    Reardon, L.
    Ameduri, R.
    Bock, M.
    Morrison, A.
    White, S.
    Wisotzkey, B.
    Kirklin, J. K.
    Godown, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (04): : S119 - S119
  • [48] Impact of Alemtuzumab Induction on Cardiac Allograft Vasculopathy in Orthotopic Heart Transplant Recipients
    Plazak, M.
    Gao, X.
    Gale, S.
    Reed, B.
    Madathil, R.
    Hammad, S.
    Ravichandran, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 758 - 759
  • [49] Cytomegalovirus infectious burden is proportional to cardiac allograft vasculopathy in heart transplant recipients
    Potena, L
    Magelli, C
    Ortolani, P
    Fearon, WF
    Grigioni, F
    Magnani, G
    Coccolo, F
    Yeung, AC
    Luikart, HI
    Hunt, SA
    Mocarski, ES
    Cooke, JP
    Lewis, DB
    Branzi, A
    Valantine, HA
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 185A - 185A
  • [50] Dipyridamole stress echocardiography for the diagnosis of cardiac allograft vasculopathy in heart transplant recipients
    Alvarez Pichel, I.
    Fernandez Cimadevilla, O. C.
    De la Hera Galarza, J. M.
    Martin Fernandez, M.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (04) : 1386 - 1387